NCT04960722: An overdue trial by BioGend Therapeutics Co.Ltd
This trial is overdue. It was due to report 8 months, 1 week ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT04960722 |
|---|---|
| Title | A Randomized, Evaluator-blinded, Controlled Study to Evaluate the Safety and Clinical Performance of OIF/β-TCP in Patients With Open Tibial Fractures in Need of Bone Grafting |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 11, 2022 |
| Completion date | Sept. 24, 2024 |
| Required reporting date | Sept. 24, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 29, 2026 |
| Days late | 247 |